ADVERTISEMENT
Feasibility and Clinical Outcomes of 48 mm Drug-Eluting Stents in the Management of Patients With Coronary Artery Disease
1. Turk-Adawi K, Sarrafzadegan N, Fadhil I, et al. Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden. Nat Rev Cardiol. 2018;15:106-119.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-2128.
3. Al Suwaidi J, Berger PB, Holmes DR Jr. Coronary artery stents. JAMA. 2000;284:1828-1836.
4. Nordmann AJ, Hengstler P, Harr T, Young J, Bucher HC. Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. Am J Med. 2004;116:253-262.
5. Mauri L, O'Malley AJ, Popma JJ, et al. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol. 2005;95:1140-1145.
6. Chang SH, Chen CC, Hsieh MJ, Wang CY, Lee CH, Hsieh IC. Lesion length impacts long term outcomes of drug-eluting stents and bare metal stents differently. PLoS One. 2013;8:e53207.
7. Valgimigli M, Tebaldi M, Borghesi M, et al. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study). JACC Cardiovasc Interv. 2014;7:20-28.
8. McKavanagh P, Zawadowski G, Ahmed N, Kutryk M. The evolution of coronary stents. Expert Rev Cardiovasc Ther. 2018;16:219-228.
9. Brunner-La Rocca HP, Kaiser C, Bernheim A, et al. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent Kosten Effektivitats trial (BASKET): an 18-month analysis. Lancet. 2007;370:1552-1559.
10. Agarwal S, Tuzcu EM, Kapadia SR. Choice and selection of treatment modalities for cardiac patients: an interventional cardiology perspective. J Am Heart Assoc. 2015;4:e002353.
11. Claessen BE, Smits PC, Kereiakes DJ, et al. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (clinical evaluation of the XIENCE V everolimus eluting coronary stent system) and COMPARE (second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) randomized trials. JACC Cardiovasc Interv. 2011;4:1209-1215.
12. Bouras G, Jhamnani S, Ng VG, et al. Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials. Catheter Cardiovasc Interv. 2017;89:984-991.
13. Li XT, Sun H, Zhang DP, et al. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with Resolute zotarolimus-eluting stents. Coron Artery Dis. 2014;25:405-411.
14. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27:1500-1510.
15. Ruchin PE, Trabattoni D, Fabbiocchi F, et al. Use of multiple overlapping sirolimus-eluting stents for treatment of long coronary artery lesions: results from a single-center registry in 318 consecutive patients. Int J Cardiol. 2009;134:231-237.
16. Chakravarty T, White AJ, Buch M, et al. Meta-analysis of incidence, clinical characteristics and implications of stent fracture. Am J Cardiol. 2010;106:1075-1080.
17. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426-2434.
18. Van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch stent thrombosis registry. J Am Coll Cardiol. 2009;53:1399-1409.
19. Bauters C, Hubert E, Prat A, et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol. 1998;31:1291-1298.
20. Kastrati A, Schomig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30:1428-1436.
21. Ellis SG, Savage M, Fischman D, et al. Restenosis after placement of Palmaz-Schatz stents in native coronary arteries. Initial results of a multicenter experience. Circulation. 1992;86:1836-1844.
22. Mathew V, Hasdai D, Holmes DR Jr, et al. Clinical outcome of patients undergoing endoluminal coronary artery reconstruction with three or more stents. J Am Coll Cardiol. 1997;30:676-681.
23. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-477.
24. Roffi M, Patrono C, Collet J-P, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315.
25. Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013;381:639-650.
26. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2018;40:87-165.
27. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39:119-177.
28. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2020;41:111-188.
29. Mehran R, Dangas G, Mintz GS, et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: intravascular ultrasound study of 2256 patients. Circulation. 2000;101:604-610.
30. Raber L, Juni P, Loffel L, et al. Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. J Am Coll Cardiol. 2010;55:1178-1188.
31. Tan CK, Tin ZL, Arshad MKM, et al. Treatment with 48-mm everolimus-eluting stents: procedural safety and 12-month patient outcome. Herz. 2019;44:419-424.
32. Jones DA, Cook S, Guttmann O, et al. P6377 The use of 48 mm everolimus eluting stents for the percutaneous treatment of long coronary lesions. Eur Heart J. 2018;39(Suppl 1).
33. Genuardi L, Burzotta F, Russo G, et al. Novel ultra-long (48 mm) everolimus-eluting stent for diffusely coronary vessels disease. Minerva Cardioangiol. 2019;67:87-93.
34. Hur S-H, Won K-B, Kim I-C, et al. Comparison of 2-year clinical outcomes between diabetic versus nondiabetic patients with acute myocardial infarction after 1-month stabilization: analysis of the prospective registry of DIAMOND (diabetic acute myocardial infarction disease) in Korea: an observational registry study. Medicine (Baltimore). 2016;95:e3882-e.
35. Lee SG, Lee CW, Hong MK, et al. Predictors of diffuse-type in-stent restenosis after coronary stent implantation. Catheter Cardiovasc Interv. 1999;47:406-409; discussion 410.
36. Hermiller JB, Raizner A, Cannon L, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1172-1179.
37. Rajesh GN, Sulaiman S, Vellani H, Sajeev CG. One-year clinical outcome of percutaneous coronary intervention with very long (≥ 40 mm) drug-eluting stent. Indian Heart J. 2018;70(Suppl 3):S285-S289.
38. Wan YL, Tsay PK, Chen CC, et al. Coronary in-stent restenosis: predisposing clinical and stent-related factors, diagnostic performance and analyses of inaccuracies in 320-row computed tomography angiography. Int J Cardiovasc Imaging. 2016;32(Suppl 1):105-115.
39. Goldberg SL, Loussararian A, De Gregorio J, Di Mario C, Albiero R, Colombo A. Predictors of diffuse and aggressive intra-stent restenosis. J Am Coll Cardiol. 2001;37:1019-1025.
40. Nayak AK, Kawamura A, Nesto RW, et al. Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J. 2006;70:1026-1029.
